盐酸埃克替尼治疗晚期复发非小细胞肺癌患者的临床疗效  

Clinical efficacy of Icotinib hydrochloride for recurrent advanced non-small cell lung cancer

作　　者：杨金霞[1] 亓小改 田莹莹[1] 王宗站[1] 邢晓波[1] YANG Jin-xia;QI Xiao-gai;TIAN Ying-ying;WANG Zong-zhan;XING Xiao-bo(First Department of Radiotherapy, Qingdao Cancer Hospital, Qingdao 266042, Chin)

机构地区：[1]山东省青岛市肿瘤医院放疗一科,青岛266042

出　　处：《中国肿瘤临床与康复》2018年第6期645-647,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨盐酸埃克替尼治疗晚期复发非小细胞肺癌患者的临床疗效。方法选取2015年4月至2017年9月间青岛市肿瘤医院收治的68例晚期复发非小细胞肺癌患者,采用随机数表法分为观察组和对照组,每组34例。对照组患者采用常规临床化疗治疗,观察组患者在对照组基础上加用盐酸埃克替尼片联合治疗,比较两组患者的临床有效率。结果观察组患者临床有效率为73.5%,高于对照组的61.8%,差异有统计学意义(P<0.05)。两组患者不良反应发生情况比较,差异无统计学意义(P>0.05)。结论盐酸埃克替尼治疗晚期复发非小细胞肺癌患者,可提高临床疗效,有一定的安全性,值得临床运用。Objective To investigate the clinical efficacy of icotinib hydrochloride for recurrent advanced non-small cell lung cancer（ NSCLC）. Methods From April 2015 to September 2017 year in September,68 patients with advanced or recurrent NSCLC treated at Qingdao Cancer Hospital were selected and randomly divided into a control group and an observation group with 34 patients in each group. The observation group used icotinib hydrochloride based on the routine chemotherapy and the control group received routine chemotherapy. Clinical efficiency was compared between the two groups. Results The efficacy rate was 73. 5% for the observation group which was higher than 61. 8% of the control group（ P〈 0. 05）. There was no statistically significant difference in adverse reactions between the two groups（ P〉 0. 05）.Conclusion Icotinib hydrochloride for advanced or recurrent NSCLC can improve the clinical efficacy with high security,and is worthy of clinical use.

关 键 词：盐酸埃克替尼 非小细胞肺肿瘤 晚期 复发 

分 类 号：R734.2[医药卫生—肿瘤]